Compare
Lifecore Biomedical, Inc. vs Gyre Therapeutics, Inc. vs Elite Pharmaceuticals Inc vs Macrogenics Inc
| Latest fiscal year | Lifecore Biomedical, Inc. LFCR | Gyre Therapeutics, Inc. GYRE | Elite Pharmaceuticals Inc ELTP | Macrogenics Inc MGNX |
|---|---|---|---|---|
| Year ended | 2025-05-25 | 2025-12-31 | 2026-03-31 | 2025-12-31 |
| Revenue | $128.87M | $116.59M | $148.87M | $149.50M |
| Revenue growth (YoY) | +0.5% | +10.2% | +77.1% | -0.3% |
| Gross margin | 31.3% | n/a | 50.4% | n/a |
| Operating margin | -13.4% | 9.9% | 33.0% | -48.7% |
| Net margin | -30.0% | 8.5% | 30.1% | -49.9% |
| Net income | -$38.72M | $9.88M | $44.87M | -$74.62M |
| EPS (Diluted) | -$1.27 | $0.02 | $0.03 | -$1.18 |
| Operating cash flow | -$206.0K | $1.01M | $23.75M | -$81.04M |
| Free cash flow | -$13.62M | -$180.0K | $22.82M | -$82.95M |
| Cash & equivalents | $8.27M | $37.07M | n/a | $57.22M |
| Total assets | $239.34M | $166.13M | $138.29M | $256.85M |
| Total liabilities | $191.91M | $23.85M | $39.41M | $201.25M |
| Shareholders' equity | $1.34M | $106.03M | $98.88M | $55.59M |
| Return on year-end equity | n/m | 9.3% | 45.4% | -134.2% |
| Shares outstanding | 37.03M | 91.31M | 1.08B | 63.32M |
Revenue, most recent five fiscal years
| Fiscal year | Lifecore Biomedical, Inc. | Gyre Therapeutics, Inc. | Elite Pharmaceuticals Inc | Macrogenics Inc |
|---|---|---|---|---|
| Latest | $128.87M Ended 2025-05-25 | $116.59M Ended 2025-12-31 | $148.87M Ended 2026-03-31 | $149.50M Ended 2025-12-31 |
| 1 year earlier | $128.26M Ended 2024-05-26 | $105.76M Ended 2024-12-31 | $84.04M Ended 2025-03-31 | $149.96M Ended 2024-12-31 |
| 2 years earlier | $103.27M Ended 2023-05-28 | $113.45M Ended 2023-12-31 | $56.63M Ended 2024-03-31 | $58.75M Ended 2023-12-31 |
| 3 years earlier | $111.27M Ended 2022-05-29 | $102.29M Ended 2022-12-31 | $34.16M Ended 2023-03-31 | $151.94M Ended 2022-12-31 |
| 4 years earlier | $100.87M Ended 2021-05-30 | $7.34M Ended 2021-12-31 | $32.26M Ended 2022-03-31 | $77.45M Ended 2021-12-31 |